COMPARISON BETWEEN THE EFFICACY OF SHORT-TERM AND FIXED PROTOCOLS OF GNRH ANTAGONIST IN IVF CYCLES

RAHMANI ELHAM¹, AHMADI SHAHNAZ^2,*, MOTAMED NILOOFAR³, GHASEMI AFSANEH⁴, ZAMANI ZOHREH⁵

¹Associate Professor, Department of Gynecologic Obstetric, Bushehr University of Medical Science, Bushehr, Iran - ²Associate Professor, Department of Gynecologic Obstetric, Iran University of Medical Sciences, Tehran, Iran - ³Associate Professor, Associate pro- fessor of Community, Bushehr University of Medical Sciences, Bushehr, Iran - ⁴Associate Professor, Department of Gynecologic Obstetric, Iran University of Medical Sciences, Tehran, Iran - ⁵Medical Student, Bushehr University of Medical Science, Bushehr, Iran

Background: Aim of this study is to compare the short-term effect of GnRH antagonist in follicular phase with fixed protocol of GnRH antagonist in IVF cycles in infertile women.

Materials and methods: The present study was conducted on 60 patients. Patients were divided into two groups of 30, based on random table of Excel. The target group received 0.25 mg per day subcutaneous Cetrorelix on days 1, 2 and 3, which was injected on the fourth day of menstruation and for the control group, fixed Cetrorelix, was started on the 6th day of cycle and continued until HCG injection. Both groups received 300 IU gonadotropin for four days that was adjusted based on the ultrasound results. Then gonadotropin consumption, number of oocytes and pregnancy rates were clinically compared.

Results: In the present study, there was no difference between the case and control group regarding pregnancy rate (P value = 0.54). Cetrorelix dose used and the total number of days of treatment were significantly different between the two groups (P value = 0.0001) and the target group used higher dose of Cetrorelix but had a lower duration of therapy. The two groups were not significan- tly different in the primary outcome, including chemical and clinical pregnancy (P value = 0.58) (P value = 0.68).

Conclusion: It was demonstrated in the present study that short-term and fixed use of GnRH antagonist in the follicular phase was not different and the short-term protocol decreases the length of treatment and increases the costs.